Download Diapositiva 1

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
BIONOSTRA GROUP
Elisabet de los Pinos, PhD
Director of Business Development
BIO-SCIENCE FORUM New York 8th November 2006
GROUP HISTORY
BIONOSTRA GROUP: founded in the year 2000 by:
CSIC Scientists
Business Executives
*CSIC: Consejo Superior de Investigaciones
Científicas- The Spanish
Highest Council of Scientific Research
CORPORATE OVERVIEW
BIONOSTRA GROUP
Foundation Date: 2000
Nº Employees:
20
Nº Patents:
6
Foundation Date: 2005
Nº Employees:
5
Nº Patents:
3
Foundation Date: 2000
Nº Employees:
25
Product Lines:
2
BIOALMA: STRATEGY
VISION: World Leading Bioinformatics company
STRATEGY:
Combine information technology and biomedical
knowledge to provide versatile solutions that meet
the specific needs of life science researchers.
BIOALMA: PRODUCTS
Functional genomics (Microarrays)
almaZen System
Provides individual researchers and core facilities with a
centralized software solution that supports the complete
microarray process. Easy-to-use tools help scientists
efficiently manage and visualize the large amount of
biological samples involved in replicated experiments,
and interpret their results.
Information extraction: almaKnowledgeServer (AKS)
AKS is a biomedical knowledge system that manages
information extracted directly from the scientific literature
using the most advanced text mining techniques. It
provides powerful search and visualization capabilities to
navigate the knowledge network and contains
functionality to easily identify relevant information.
BIOALMA: MARKETING / SALES
USA
Europe
Yashusiro Yogo
Chris Wasden
Head of Marketing
Japan
Bilal Yahouie
Head of Marketing
Head of Marketing
Chris Hoover
Mr. Tanaka
Marketing TimeLogic
Representative
MICROBIONTA
•
Early Stage Biotechnology Company
•
Strategy: Development of New Technologies for
Diagnosis and Therapy based on the
expression of Recombinant Antibodies in
Bacteria
•
Technology Platforms:
- Recombinant Antibody Secretion in Bacteria
- Bacterial Display of antibodies
MICROBIONTA: TECHNOLOGY
Recombinant Ab
Ab
BACTERIA
Single Chain Antibody (scFv)
Microbionta owns
the Technology
which enables the
expression of
recombinant Ab in
Bacteria
Camelbody
Antibody Secretion
INDUSTRIAL
APPLICATIONS
• Antibody Secretion for the
treatment of Intestinal
Disorders
Bacterial Display
• Antibody Selection
• Markers for Diagnosis
BIONOSTRA: STRATEGY
VISION
World leader in the development of vaccines
based on Virus Like Particles
STRATEGY
Discovery and Drug Development of new
Prophylactic and Therapeutic vaccines based on
its
BIONIB® VIRUS LIKE PARTICLE TECHNOLOGY
PLATFORM
BIONIB TECHNOLOGY PLATFORM
BIONIB® TECHNOLOGY PLATFORM
What are BIONIB® Virus Like Particles?
Our technology platform BIONIB® has developed and optimized the large scale production
of nanometric particles known as VLPs (virus like particles) structural proteins resembling the live
virus particle.
What makes this technology valuable?
•Biological security (lack of genetic material)
•Long term stability
•Low cost industrial production in yeast
•Multi-epitope expression
•Highly immunogenic (no pre-existing antibodies in humans)
•Induction of antibodies against disease-related molecules
•Activation of cytotoxic T cells
•Possibility for nucleic acid encapsidation
BIONOSTRA: PIPELINE
PRODUCT PIPELINE
Human Health
Infectious disease
Cardiovascular
disease
Product
Indication
BIONIB V005
Influenza
BIONIB V004
Malaria
BIONIB GT001
FH*
BIONIB GT002
PAD**
Validation
Lead optimization
Pre-clinical
IND Filing
Phase I
Phase II
*FH: Familial
Hypercholesterolemia
**PAD: Peripheral Arterial Disease
Animal Health
Infectious disease Product
Indication
Specie
BIONIB Vv001
Gumboro
Poultry
BIONIB Vv002
Influenza
Poultry
BIONIB Vv003
FMDV*
Swine
BIONIB Vv004
Gumboro/Marek
Poultry
* FMDV: Foot and Mouth Disease Virus
Validation
Lead optimization
Phase I
Phase II
Phase III
BIONOSTRA: Services and Contract Research
Biotech Services
Food
services
Animal
Facilities
Molecular
Biology Services
•
•
•
•
•
•
•
GMO´s detection
Race/ Strain / Varieties Identification
Species Identification (animal/Vegetables)
Winery Industry ( Grape/Yeast Id.)
Water (detection of endotoxins)
Allergens Detection
Hormones/Antibiotics Detection
• Health Monitoring
• Molecular Markers for Genetic
Background
• Speed-Congenic
•
•
•
•
•
•
Sequencing
Cloning
Protein Expression
Antibody Production
Microsatellite Development
Quantitative PCR
Related documents